Revvity Inc. (RVTY)
NYSE: RVTY
· Real-Time Price · USD
86.61
0.91 (1.06%)
At close: Sep 05, 2025, 3:59 PM
86.50
-0.13%
After-hours: Sep 05, 2025, 05:16 PM EDT
Revvity Revenue Breakdown
| Period Ending | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 |
|---|---|---|---|---|---|
| Diagnostics Revenue | 354.39M | 324.37M | 1.12B | 383.13M | 377.84M |
| Diagnostics Revenue Growth | +9.25% | -70.98% | +191.74% | +1.40% | n/a |
| Life Sciences Revenue | 365.9M | 340.39M | 953.22M | 300.92M | 313.85M |
| Life Sciences Revenue Growth | +7.49% | -64.29% | +216.77% | -4.12% | n/a |
Revenue by Geography
| Period Ending | Jun 29, 2025 | Mar 30, 2025 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|
| Americas Revenue | 323.58M | 304.63M | 302.32M | 307.78M | 294.35M |
| Americas Revenue Growth | +6.22% | +0.76% | -1.77% | +4.56% | n/a |
| Asia Revenue | 193.07M | 178.34M | 199.69M | 199.31M | 177M |
| Asia Revenue Growth | +8.26% | -10.69% | +0.19% | +12.60% | n/a |
| Europe Revenue | 203.63M | 181.79M | 182.04M | 184.59M | 178.56M |
| Europe Revenue Growth | +12.01% | -0.14% | -1.38% | +3.37% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 29, 2025 | Mar 30, 2025 | Dec 29, 2024 | Sep 29, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Apr 2, 2023 | Jan 1, 2023 | Oct 2, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 163.24M | 185.68M | 178.19M | 233.07M | 235.85M | 230.58M | 144.9M | 226.23M | 233.99M | 228.87M | 140.86M | 177.4M | 250.26M | 256.77M | 178.71M | 170.09M | 234.08M | 212.87M | 223.07M | 195.49M | 193.21M | 152.24M | 178.56M | 175.23M | 174.59M | 168.06M | 176.4M | 167.83M | 173.03M | 171.71M | 200.97M | 108.91M | 133.86M | 131.68M | 146.09M | 131.34M | 153.99M | 147.54M | 158.5M | 147.73M | 146.74M | 145.87M |
| Selling, General, and Administrative Revenue Growth | -12.09% | +4.20% | -23.55% | -1.18% | +2.29% | +59.13% | -35.95% | -3.31% | +2.24% | +62.48% | -20.60% | -29.11% | -2.53% | +43.68% | +5.06% | -27.34% | +9.96% | -4.57% | +14.11% | +1.18% | +26.90% | -14.74% | +1.90% | +0.37% | +3.89% | -4.73% | +5.11% | -3.01% | +0.77% | -14.56% | +84.54% | -18.64% | +1.65% | -9.86% | +11.23% | -14.71% | +4.37% | -6.91% | +7.30% | +0.67% | +0.60% | n/a |
| Research and Development Revenue | 53.27M | 53.6M | 49.21M | 49.14M | 48.13M | 50.36M | 49.6M | 53.04M | 57.25M | 56.69M | 54.54M | 53.52M | 56.04M | 57.52M | 60.58M | 49.42M | 65.82M | 60.22M | 56.82M | 50.13M | 49.52M | 48.91M | 47.64M | 45.38M | 48.34M | 47.98M | 47.87M | 45.15M | 47.2M | 45.98M | 37.63M | 34.79M | 33.56M | 33.29M | 32.93M | 33.08M | 35.01M | 33.78M | 30.03M | 31.09M | 32.68M | 32.12M |
| Research and Development Revenue Growth | -0.61% | +8.92% | +0.13% | +2.10% | -4.42% | +1.54% | -6.49% | -7.36% | +0.99% | +3.95% | +1.90% | -4.49% | -2.59% | -5.05% | +22.59% | -24.92% | +9.31% | +5.97% | +13.35% | +1.23% | +1.24% | +2.68% | +4.98% | -6.14% | +0.76% | +0.23% | +6.03% | -4.34% | +2.64% | +22.19% | +8.18% | +3.66% | +0.82% | +1.10% | -0.45% | -5.52% | +3.62% | +12.50% | -3.42% | -4.86% | +1.75% | n/a |